CN Patent

CN103635189B — 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗

Assigned to Novartis AG · Expires 2016-05-04 · 10y expired

What this patent protects

用于治疗癌症的CDK4/6抑制剂和P3激酶抑制剂组合。

USPTO Abstract

用于治疗癌症的CDK4/6抑制剂和P3激酶抑制剂组合。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN103635189B
Jurisdiction: CN
Classification: —
Expires: 2016-05-04
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.